诱导多能干细胞衍生的嵌合抗原受体自然杀伤细胞：用于系统性硬化症的现成细胞疗法。
iPSC-derived CAR-NK cells: Off-the-shelf cellular therapy for systemic sclerosis.
作者信息
Daher May, Rezvani Katayoun
机构信息
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Institute for Cell Therapy Discovery & Innovation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Cell. 2025 Aug 7;188(16):4173-4174. doi: 10.1016/j.cell.2025.07.007.
Chimeric antigen receptor (CAR) T cell therapy has opened new possibilities for patients with refractory autoimmune diseases such as systemic sclerosis, but personalized manufacturing and treatment-related toxicities limit its broader use. In this preview, we discuss the first clinical application of an off-the-shelf, iPSC-derived CAR-NK cell product in systemic sclerosis as reported by Wang et al. in this issue of Cell.
嵌合抗原受体（CAR）T细胞疗法为系统性硬化症等难治性自身免疫性疾病患者开辟了新的可能性，但个性化制造和治疗相关毒性限制了其更广泛的应用。在本预览中，我们讨论了Wang等人在本期《细胞》杂志上报道的现成的、诱导多能干细胞（iPSC）衍生的CAR-NK细胞产品在系统性硬化症中的首次临床应用。
Zotero 插件